From New Board Appointment Ann.
IMO, Dr Paul up-beat, good and positive on the Co.
Dr Paul Kasian commented “The company is extremely happy to welcome Mr Burrows to the boardgiven his wealth of experience, in assisting companies in both commercialization of opportunities andcorporate governance, in what is a very exciting time for the company.”
From the Preliminary Final Report p2.
GTG’s first-to-market genetic risk assessment test for colorectal cancer is also now launched.
This is the first of asuite of ground-breaking new products GTG will deliver in the next 12 months.
Further genetic risk assessment tests under development:
• Cardiovascular Disease - target launch late 2019
• Type 2 Diabetes - target launch late 2019
• Prostate Cancer - 2020• Melanoma - 2020
Got to like them apples.
Rome wasn't built in a day...
.
- Forums
- ASX - By Stock
- Ann: New Board Appointment
From New Board Appointment Ann. IMO, Dr Paul up-beat, good and...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GTG (ASX) to my watchlist
|
|||||
Last
5.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.270M |
Open | High | Low | Value | Volume |
5.0¢ | 5.1¢ | 5.0¢ | $6.24K | 123.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 208333 | 4.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.2¢ | 19249 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 80 | 0.047 |
1 | 22222 | 0.045 |
1 | 227272 | 0.044 |
1 | 55000 | 0.043 |
2 | 205000 | 0.042 |
Price($) | Vol. | No. |
---|---|---|
0.052 | 19249 | 1 |
0.053 | 25000 | 1 |
0.058 | 10000 | 1 |
0.059 | 73500 | 1 |
0.065 | 35590 | 1 |
Last trade - 15.36pm 19/07/2024 (20 minute delay) ? |
Featured News
GTG (ASX) Chart |